Cargando…
Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: A meta-analysis of randomized controlled trials and observational studies
BACKGROUND: Vonoprazan is a potassium-competitive acid blocker (P-CAB) that is frequently used in Japan for Helicobacter pylori (H. pylori) eradication, treatment of gastroesophageal reflux disease, and treatment of post endoscopic submucosal dissection (ESD) complications. We sought to determine if...
Autores principales: | Martin, Zhou, Yi, Meng, Chun-Xu, Takagi, Tatsuya, Tian, Yu-Shi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478518/ https://www.ncbi.nlm.nih.gov/pubmed/32118778 http://dx.doi.org/10.1097/MD.0000000000019357 |
Ejemplares similares
-
Vonoprazan versus proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: Protocol for meta-analysis of randomized controlled trials and observational studies
por: Martin,, et al.
Publicado: (2019) -
Rebamipide Plus Proton Pump Inhibitor Versus Proton Pump Inhibitor Alone in the Treatment of Endoscopic Submucosal Dissection-Induced Gastric Ulcer: Retracted: A Meta-Analysis of Randomized Controlled Trials
por: Xiong, Ji, et al.
Publicado: (2014) -
Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers
por: Takahashi, Kazuya, et al.
Publicado: (2016) -
Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: A systematic review with meta-analysis
por: Kang, Hyun, et al.
Publicado: (2019) -
Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease
por: Gotoh, Yasuhiko, et al.
Publicado: (2020)